NCT03140488 (OPS) is a Phase 4 clinical trial of Oxytocin in Obesity, sponsored by University of Arizona.

Who is sponsoring NCT03140488?

NCT03140488 is sponsored by University of Arizona.

What drugs are being tested in NCT03140488?

Interventions in NCT03140488: Oxytocin.

What condition does NCT03140488 study?

NCT03140488 studies Obesity, Labor, Induced, Oxytocin.

Is NCT03140488 still recruiting?

NCT03140488 is currently completed. Last updated 20 December 2022.

Are results published for NCT03140488?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-12-20 · How we verify

NCT03140488: OPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxytocin Dosage to Decrease Induction Duration

Completed Phase 4 Results posted Last updated 20 December 2022

What this trial tests

Phase 4 trial testing Oxytocin in Obesity in 140 participants. Completed in 5 September 2019.

Timeline

5 June 2017

Primary endpoint
12 October 2018

5 September 2019

Quick facts

Lead sponsor	University of Arizona
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	140
Start date	5 June 2017
Primary completion	12 October 2018
Estimated completion	5 September 2019
Sites	1 location across United States

Drugs / interventions tested

Oxytocin (OXYTOCIN) — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →
Labor, Induced — all drugs for Labor, Induced →
Oxytocin — all drugs for Oxytocin →

Sponsor

University of Arizona

Who can join

18 and older, female only, with Obesity or Labor, Induced. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Length of Time to Delivery Primary · Start of induction to Delivery

Number of minutes from induction of labor with oxytocin infusion to delivery of infant, no maximum amount of time specified.

Group	Value	95% CI
Lean-Control	796	± 411
Lean-Intervention	694	± 466
Obese-Control	715	± 497
Obese-Intervention	762	± 594

Maximum Oxytocin Infusion Rate Secondary · Start of induction to Delivery

rate measured in milliunits/minute during induction of labour, no time limit applied.

Group	Value	95% CI
Lean-Control	14.85	± 7.16
Lean-Intervention	33.00	± 25.64
Obese-Control	17.14	± 10.99
Obese-Intervention	39.60	± 21.09

Number of Participants With Terbutaline Use Secondary · Start of induction to Delivery

If terbutaline was injected during labor to decrease number or strength of contraction

Group	Value	95% CI
Lean-Control	0
Lean-Intervention	0
Obese-Control	0
Obese-Intervention	1

Rate of Cesarean Delivery Secondary · Start of induction to Delivery

total number of patients who undergo cesarean delivery

Group	Value	95% CI
Lean-Control	5
Lean-Intervention	2
Obese-Control	4
Obese-Intervention	1

Rate of Cesarean Delivery for Labor Arrest Secondary · Start of induction to Delivery

Number of patients who undergo cesarean delivery due to labor arrest/ failed induction

Group	Value	95% CI
Lean-Control	1
Lean-Intervention	1
Obese-Control	3
Obese-Intervention	0

Maternal Blood Loss Secondary · At delivery

Blood loss in milliliters

Group	Value	95% CI
Lean-Control	391.14	± 207.96
Lean-Intervention	358.57	± 166.49
Obese-Control	404.29	± 226.99
Obese-Intervention	491.43	± 342.89

Number of Neonates With Apgar Score <7 Secondary · 5 minutes after birth

5 minute Apgar Score \<7 \*Apgar is an acronym for which each criterion is given a minimum of 0 and maximum of 2 points: Appearance (skin color), Pulse (heart rate), Grimace (reflex irritability), Activity (muscle tone), Respiration

Group	Value	95% CI
Lean-Control	0
Lean-Intervention	3
Obese-Control	0
Obese-Intervention	1

Sponsor's own description

This is a randomized controlled trial in which women are allocated either 'high dose' or 'low dose' oxytocin infusions for induction of labour. The randomization is stratified by maternal body mass index.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07188207 — Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section · NA · not yet recruiting
NCT06968481 — Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage · Phase 2 · not yet recruiting
NCT07265180 — Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison · NA · recruiting
NCT07119398 — Oxytocin/Foley vs. Oxytocin for Induction in Patients With PPROM · Phase 4 · recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03140488 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 20 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03140488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing